Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
116 Leser
Artikel bewerten:
(0)

Talogy enables early careers success with new future-ready solutions

Finanznachrichten News

GLENDALE, Calif., Jan. 22, 2025 /PRNewswire/ -- Talogy, a world-leading talent management solution provider, has launched Spotlight, a comprehensive, early career assessment solution, developed following extensive research into early career professionals and the demands on people hiring them.

Talogy company logo

Backed by global research of more than 1200 managers, recent employees, and early career seekers, Talogy Spotlight is ideal for enterprise organizations, looking to discover the brightest and most versatile early career professionals.

By assessing the competencies and skills needed for both early and long-term career success, Talogy Spotlight goes beyond a candidate's resume to unlock their full potential and support an organization in the early stages of developing a talent pipeline.

Traditionally, early career professionals can struggle to gain professional experience in the workplace. Spotlight focuses on 11 core competencies that research has found to be key indicators of success. In the absence of work experience, these indicators can be very useful in predicting future job performance.

Talogy's expert consultants work with clients to design a customizable and flexible early careers solution which informs as well as assesses a candidate. To help keep users on task, Spotlight has been developed to be more engaging for candidates and includes real-world scenario and storylines that introduce them to an organization and its brand values.

It combines a variety of assessment techniques including Situational Judgement Testing (SJT), personality, and cognitive assessments, and can also be combined with values assessment, competency-based interviews, or assessment centers.

At the end of the process, both candidate and hiring manager are provided feedback around strengths and areas for further development. A more holistic, statistical, view is also supported, allowing analysis of multiple applications to determine strengths and weaknesses across candidates, and the impact it might have longer term on the organization.

Ted Kinney, Vice President, R&D, at Talogy, said, "With an aging workforce, and an increasing trend towards early retirement, attracting, identifying, and engaging the right talent is crucial for the ongoing success of an organization. Hiring managers need to think more strategically, looking at both the immediate role that needs to be fulfilled, as well as the impact their recruitment decisions make on the long-term success of the company."

Learn more here about Talogy Spotlight early career solutions

About Talogy
At Talogy, we're proud to be one of the world's leading talent management solution providers. Crafting personalized solutions to help select, develop, and transform talent and organizations worldwide. Partnering with organizations to truly understand their challenges, inside out to help them make the best data-driven people decisions. Combining 75+ years of expertise, our extensive content library, and innovative technology, we help clients find, build, and grow the best talent. www.talogy.com

Logo - https://mma.prnewswire.com/media/1727124/Talogy_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/talogy-enables-early-careers-success-with-new-future-ready-solutions-302348109.html

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.